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Commentary on “Training family members to manage heroin overdose and administer 
naloxone: Randomised trial of effects on knowledge and attitudes” 
The notion of providing heroin users or their peers with naloxone, a pure opioid antagonist, 
as an emergency intervention for heroin overdose has a long history (1).  Reports of 
implementation and evaluation of take-home naloxone (THN) programs often mention 
‘family members’ among potential overdose witnesses in their target audience (2) or for 
training programs (e.g. 3) with Strang and colleagues the first to focus on family members as 
an overlooked group of potential overdose witnesses (7). Training family members and 
others who are non-injecting drug users (IDUs) may be important in increasing the pool of 
trained responders, as some IDUs may withdraw from their peers due to trauma associated 
with witnessing overdoses (4). However, many THN programs have tended to train peer 
IDUs rather than their family members (e.g. 5, 6).  
Take-home naloxone programs are increasingly being evaluated and implemented around 
the globe. Therefore, the development and validation of the Opioid Overdose Knowledge 
Scale (OOKS) and Opioid Overdose Attitudes Scale (OOAS) will facilitate the comparison of 
results across studies. We thank the authors for the rigor they have applied to this work 
(8,9). However, the psychometric properties of the OOKS and OOAS were assessed among 
family members and relevant health care professionals. As has been noted, family members 
have not been routinely included in overdose prevention and management.  It is not entirely 
clear what proportion, if any, of the sample in the current paper were active IDUs, but 
regardless, it would be important for researchers to now validate the OOKS and the OOAS 
with peer opioid users. 
In the current study participants were instructed in a two-stage process that involved 
injecting half of a pre-filled syringe, withdrawing the needle, placing the uncapped syringe 
back in its box and observing recovery for two minutes. If no response was observed, the 
remainder of the naloxone would be injected  (9). Whilst we understand the argument that 
the two-dose pre-filled syringe may be attractive from a cost point of view, and recognise 
that this is an important consideration in maximising coverage of naloxone, there are 
obvious concerns about the risk of needle stick injuries and transmission of blood borne 
viruses. In Australia, naloxone programs are now using two 0.4mg/ml 1ml pre-filled 
minijets® of naloxone. We also note the use of 2.0mg/2ml intranasal forms of naloxone in a 
number of states in the USA  (10).  Although there are calls for more research on the 
pharmacokinetics of intranasal (IN) naloxone (10), the advantages are that it removes the 
risk of needle stick, simplifies the training as there is no need to cover intramuscular (IM) 
injection and managing sharps, and is a less daunting prospect for use by non-IDU potential 
overdose witnesses such as family members and others. We note that given this, items in 
the OOKS which currently only refer to the IM injection route of administration will need to 
be altered to accommodate the IN route (11).  
As the author’s note, whilst knowledge and attitudes are important, a stronger outcome 
measure would be the number of overdose events successfully managed at follow-up but a 
far larger study design would be required to demonstrate such a change (1). Nevertheless, 
in the current study with only 3 months of follow-up, 13 overdoses were observed, mostly 
victims were appropriately put in the recovery position and an ambulance called: in two 
cases THN was used to reverse opiate overdoses whilst naloxone was administered by 
ambulance personnel in a further six cases. Training family members or peers in overdose 
management also means that they may be able to recognising symptoms of overdose and 
enact emergency procedures such as calling an ambulance, checking airways, rescue 
breathing and placing people in the recovery position even in the absence of naloxone. 
The excellent work done by Williams and colleagues in the development of the OOAS and 
the OOKS should now be applied to future evaluations of overdose prevention programs 
incorporating naloxone. These should have the sample sizes necessary to demonstrate the 
link between knowledge change, attitude change and behavioural outcomes to support the 
growing evidence base for this important intervention to reduce opioid related morbidity 
and mortality.   
This randomised trial of THN by Williams and colleagues makes a further important 
contribution to the evidence base supporting the provision of naloxone outside of medical 
settings and makes the timely case that family members should routinely be afforded 
training in overdose prevention incorporating naloxone  (9).   
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